2012 OPEN FORUM Abstracts
META-ANALYSIS OF THE IMPACT OF STATINS ON THE MORTALITY AND THE EXACERBATION RATE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Alexandros G. Mathioudakis1, Victoria Chatzimavridou-Grigoriadou2, Prodromos Kanavidis2, Stavroula G. Amanetopoulou2, Ioannis Gialmanidis2, Efstathia I. Evangelopoulou2, Georgios A. Mathioudakis2; 1Medical Department, Macclesfield District General Hospital, Macclesfield, United Kingdom; 2Respiratory Department, General Hospital of Nikaia âSt. Panteleimonâ, Piraeus, Greece
Background: Medical therapy of Chronic Obstructive Pulmonary Disease (COPD) currently aims to reduce the exacerbation rates and to improve the quality of life. Only longterm oxygen administration has been shown to modify the mortality of the disease. In this meta-analysis of case-control and cohort studies we accumulated current evidence regarding the impact of statins on the survival rate of these patients. Methods: A systematic search in the electronic databases of the Cochrane Library, Medline and Scopus was conducted by two independent authors (May 2012). Case control and cohort studies on the impact of statins on the mortality and the exacerbation rate of patients with COPD. Data on total mortality and exacerbation rates were extracted and missing data were obtained from authors. Relative risk (RR) for total mortality and the exacerbation rate were calculated for each study and pooled. Results: 12 Case-control studies and cohorts, evaluating 231978 patients met the inclusion criteria. Statin administration was associated with a decreased risk of all-cause mortality (relative risk 0.635, 95% confidence interval 0.579 to 0.697) and a decreased exacerbation rate (relative risk 0.472, 95% confidence interval 0.304 to 0.732). Conclusion: Statistically significant reduction of the all-cause mortality and the exacerbation rate of COPD was found in patients who were receiving statins. 1A level of evidence cannot be deduced by our study, but our results enhance the level of evidence and encourage the conduction of clinical trials. Sponsored Research - None